Publikation
Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study.
Wissenschaftlicher Artikel/Review - 01.07.2022
Hatemi Gülen, Mahr Alfred, Takeno Mitsuhiro, Kim Doyoung, Melikoğlu Melike, Cheng Sue, McCue Shannon, Paris Maria, Chen Mindy, Yazici Yusuf
Bereiche
PubMed
DOI
Kontakt
Zitation
Hatemi G, Mahr A, Takeno M, Kim D, Melikoğlu M, Cheng S, McCue S, Paris M, Chen M, Yazici Y. Impact of apremilast on quality of life in Behçet's syndrome: analysis of the phase 3 RELIEF study. RMD Open 2022; 8
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
RMD Open 2022; 8
Veröffentlichungsdatum
01.07.2022
eISSN (Online)
2056-5933
Kurzbeschreibung/Zielsetzung
To assess apremilast's impact on patient quality of life (QoL) in active Behçet's syndrome and correlations between improvement in patients' QoL and efficacy measures in the phase 3 RELIEF study.